Conclusion
Rituximab is considered an important treatment option in patients with
moderate to severe refractory pemphigus vulgaris. RTX has been shown to
be effective and well-tolerated in several autoimmune conditions.
However, there are still concerns about its long-term adverse effects.
Clinicians should be vigilant for potential acute or delayed serum
sickness as possible adverse reactions to weigh the risks and benefits
of continuing/reintroducing RTX for patients with pemphigus vulgaris.
Further studies reporting the adverse effects of RTX are required to
establish its safety and tolerability.